Form 4: Monopar Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Chandler Robinson, Chief Executive Officer and a Director of Monopar Therapeutics, sold 29,056 shares of common stock on September 24, 2026.
Summary
- Option exercise/conversion: acquired 14,056 Common Stock at $30.00 ($421,680) on September 24, 2026; holds 113,323 after (Direct).
- Option exercise/conversion: acquired 15,000 Common Stock at $14.00 ($210,000) on September 24, 2026; holds 128,323 after (Direct).
- Open-market sale: disposed of 10,450 Common Stock at $87.15 ($910,718) on September 24, 2026; holds 117,873 after (Direct).
- Open-market sale: disposed of 9,638 Common Stock at $87.96 ($847,758) on September 24, 2026; holds 108,235 after (Direct).
- Open-market sale: disposed of 8,368 Common Stock at $88.97 ($744,501) on September 24, 2026; holds 99,867 after (Direct).
- Open-market sale: disposed of 600 Common Stock at $89.79 ($53,874) on September 24, 2026; holds 99,267 after (Direct).
- Option exercise/conversion: disposed of 14,056 Stock Option on September 24, 2026; holds 15,044 after (Direct).
- Option exercise/conversion: disposed of 15,000 Stock Option on September 24, 2026; holds 27,204 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,556,851 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Chandler Robinson — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-24 | Option exercise/conversion | Common Stock | 14,056 | $30 | $421.7K | 113,323 |
| 2026-09-24 | Option exercise/conversion | Common Stock | 15,000 | $14 | $210.0K | 128,323 |
| 2026-09-24 | Open-market sale | Common Stock | 10,450 | $87 | $910.7K | 117,873 |
| 2026-09-24 | Open-market sale | Common Stock | 9,638 | $88 | $847.8K | 108,235 |
| 2026-09-24 | Open-market sale | Common Stock | 8,368 | $89 | $744.5K | 99,867 |
| 2026-09-24 | Open-market sale | Common Stock | 600 | $90 | $53.9K | 99,267 |
| 2026-09-24 | Option exercise/conversion | Stock Option | 14,056 | — | — | 15,044 |
| 2026-09-24 | Option exercise/conversion | Stock Option | 15,000 | — | — | 27,204 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-24 | Option exercise/conversion (14,056 shares) |
| 2026-09-24 | Option exercise/conversion (15,000 shares) |
| 2026-09-24 | Open-market sale (10,450 shares) |
| 2026-09-24 | Open-market sale (9,638 shares) |
| 2026-09-24 | Open-market sale (8,368 shares) |
| 2026-09-24 | Open-market sale (600 shares) |
| 2026-09-24 | Option exercise/conversion (14,056 shares) |
| 2026-09-24 | Option exercise/conversion (15,000 shares) |
Keywords
insider transaction, Form 4, MNPR, Monopar Therapeutics, bearish, Chandler Robinson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.